Boehringer Ingelheim and Eli Lilly Alliance
This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience and pioneering history in diabetes.
Modules
EA:
1.5
MO:
0
RP:
0
Total:
1.5
On-demand webinar: Chronic kidney disease - what GPs can do to prevent progression and premature death
Audits
EA:
1.5
MO:
4
RP:
1
Total:
6.5
Clinical audit: Chronic kidney disease (CKD) - preventing progression and premature death in general practice
Audits
EA:
1
MO:
4
RP:
1
Total:
6
Clinical audit: Management of heart failure with reduced ejection fraction